An observational study in Retinal Disease, Healthy and Glaucoma, sponsored by Optos, PLC. Recruiting at 4 sites in United States. Open to participants aged 22 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by Optos, PLC · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 162 studies in Retinal Diseases with a site in United States — 25 open to participants now, 41 under way, 5 of them phase 3. Retinal Diseases · United States.
Among the 162 studies in Retinal Diseases with a site in United States, this one is the 22nd largest by planned enrollment of the 51 observational ones that give a count, is one of 7 that started in 2025, is one of 51 observational ones, reaches primary completion later than 2 of the 37 other live ones, and was the 157th registered.
333 studies on the registry are indexed under Retinal Diseases; 59 are open to participants now.
Browse Retinal Diseases studies →25 of the 162 studies in Retinal Diseases with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 0 days–9 mo
Duke University · Sites in United States
Ages 1 mo+ · Healthy volunteers
Life Biosciences Inc. · Sites in United States
Ages 40–85
Washington University School of Medicine · Sites in United States
Ages 50+
MediBeacon · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 44 Retinal Diseases studies recruiting now, 30 (68%) set no upper age limit and 4 (9%) stop at 75 or younger; 16 take children under 18; 19 take healthy volunteers.
This study: 22 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
162 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 49 · Phase 3 21 · Phase 4 1
First in 1992; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is close to the median of 200 across 118 observational studies indexed under Retinal Diseases.
Median enrollment 36 across the 111 interventional studies, 120 across the 51 observational. Of the 113 that completed or were terminated, 44 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
86 of 162 have an industry lead sponsor. The 10 most frequent:
Optos, PLC is the lead sponsor of 18 studies on the registry; 3 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
Optos, PLC has 7 studies filed under Retinal Diseases — fewer than ten, so there is no comparison to draw.
14 of the studies in Retinal Diseases with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04704921Phase 3AbbViePivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | 2026-12 |
| NCT05750589Phase 3iRenix Medical, Inc.Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections | 2027-01-31 |
| NCT06891443Phase 3Laboratoires TheaStudy to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) | 2027-11 |
| NCT06380075University of Wisconsin, MadisonCOmparison of Clarus and Optos Ultrawide Field Imaging Systems for Inherited Retinal Disease | 2026-12 |
| NCT04008121MediBeaconFeasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium | 2026-12 |
Add all 14 to your calendar (.ics) → With an account.
Among the 162 studies in Retinal Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to gather Optical Coherence Tomography (OCT) data on normal and diseased eyes
Participants with healthy, glaucoma, retinal disease and corneal disease located in different geographic locations in the US
Inclusion/Exclusion Criteria Inclusion Criteria for Retinal Disease Group
Exclusion Criteria for Retinal Disease Group
Inclusion Criteria for Glaucoma Group
History of Visual field defects within the previous year from the study visit or measured the day of the study visit consistent with glaucomatous optic nerve damage with at least one of the following two findings:
Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities:
Exclusion Criteria for Glaucoma Group
1. Participants 22 years of age or older on the date of informed consent 2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent 3. Participants presenting at the site with corneal disease, for example but not limited to, corneal disorders due to contact lens wear, post-refractive surgery, dry eye, keratoconus 4. Participant is able to comply with the study procedures.
Exclusion Criteria for Corneal Group
Inclusion Criteria for Normal Group
Exclusion Criteria for Normal Group
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: OCT
Device: OCT
Device: OCT
Device: OCT
A10900 is an optical coherence tomography device
Number of OCT Scans
Time frame: 1 year
Not enrolling at this site.
Plan to share: Yes — This is included in the participant's informed consent. Images, demographics, ophthalmic assessments and examinations, visual fields, and ophthalmic and medical history.
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for May 2026, 10 months after the start.
Of 54 observational studies under Retinal Diseases, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 17. This study's planned 10 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Optos, PLC